Akero Therapeutics Inc
Change company Symbol lookup
Select an option...
AKRO Akero Therapeutics Inc
MRTX Mirati Therapeutics Inc
SIRC Solar Integrated Roofing Corp
CHSTY China High Speed Transmission Equipment Group Co Ltd
TTMZF Datable Technology Corp
WVFC W V S Financial Corp
WHLM Wilhelmina International Inc
SON Sonoco Products Co
VIRX Viracta Therapeutics Inc
PFS Provident Financial Services Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Akero Therapeutics Inc. is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases. The Company is engaged to treat non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 (FGF21), which is a hormone that protects against cellular stress and regulates the metabolism of lipids, carbohydrates and proteins throughout the body. EFX is being evaluated in two Phase IIb clinical trials in patients with biopsy-confirmed NASH: the study in pre-cirrhotic patients with F2-F3 fibrosis and the SYMMETRY study in cirrhotic patients with compensated F4 fibrosis. Its EFX program is focused on patients with cirrhotic NASH (F4, compensated) in Phase IIb clinical trial.

Closing Price
$41.54
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Below Average)
Volume:
504,619

10-day average volume:
611,670
504,619

Bed Bath & Beyond Q2 sales $1.437 bln vs. $1.985 bln a year ago; FactSet consensus $1.447 bln

7:32 am ET September 29, 2022 (MarketWatch)
Print
	

(END) Dow Jones Newswires

September 29, 2022 07:32 ET (11:32 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.